ATE360033T1 - Ortsspezifische proteinmodifizierung durch mutagenese - Google Patents
Ortsspezifische proteinmodifizierung durch mutageneseInfo
- Publication number
- ATE360033T1 ATE360033T1 AT99930486T AT99930486T ATE360033T1 AT E360033 T1 ATE360033 T1 AT E360033T1 AT 99930486 T AT99930486 T AT 99930486T AT 99930486 T AT99930486 T AT 99930486T AT E360033 T1 ATE360033 T1 AT E360033T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- polyethylene glycol
- amino acid
- acid residue
- mutagenesis
- Prior art date
Links
- 238000002703 mutagenesis Methods 0.000 title 1
- 231100000350 mutagenesis Toxicity 0.000 title 1
- 230000009145 protein modification Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 239000002202 Polyethylene glycol Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 229920001223 polyethylene glycol Polymers 0.000 abstract 4
- 125000000539 amino acid group Chemical group 0.000 abstract 3
- 230000021615 conjugation Effects 0.000 abstract 2
- 230000001268 conjugating effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 102000035118 modified proteins Human genes 0.000 abstract 1
- 108091005573 modified proteins Proteins 0.000 abstract 1
- 230000004952 protein activity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/102,530 US6451986B1 (en) | 1998-06-22 | 1998-06-22 | Site specific protein modification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE360033T1 true ATE360033T1 (de) | 2007-05-15 |
Family
ID=22290346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99930486T ATE360033T1 (de) | 1998-06-22 | 1999-06-18 | Ortsspezifische proteinmodifizierung durch mutagenese |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US6451986B1 (de) |
| EP (2) | EP1090036B1 (de) |
| JP (1) | JP3578991B2 (de) |
| AT (1) | ATE360033T1 (de) |
| AU (1) | AU767630B2 (de) |
| CA (1) | CA2331337C (de) |
| DE (1) | DE69935855T2 (de) |
| ES (1) | ES2285843T3 (de) |
| NZ (1) | NZ509424A (de) |
| WO (1) | WO1999067291A2 (de) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451986B1 (en) * | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US7144574B2 (en) | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
| US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
| US7431921B2 (en) | 1999-08-27 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
| CN1309423C (zh) | 1999-11-12 | 2007-04-11 | 马克西根控股公司 | 干扰素γ偶联物 |
| CA2390292A1 (en) | 1999-11-12 | 2001-05-25 | Maxygen Holdings Ltd. | Interferon gamma conjugates |
| US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US6831158B2 (en) | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US6646110B2 (en) | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
| JP2003525612A (ja) * | 2000-03-02 | 2003-09-02 | ゼンコー | ＴＮＦ−α関連障害の処置のための変種ＴＮＦ−αタンパク質の設計および発見 |
| WO2001093914A2 (en) | 2000-06-08 | 2001-12-13 | La Jolla Pharmaceutical Company | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| WO2002036626A1 (en) * | 2000-11-02 | 2002-05-10 | Maxygen Aps | Single-chain multimeric polypeptides |
| WO2002074806A2 (en) | 2001-02-27 | 2002-09-26 | Maxygen Aps | New interferon beta-like molecules |
| US7038015B2 (en) | 2001-04-06 | 2006-05-02 | Maxygen Holdings, Ltd. | Interferon gamma polypeptide variants |
| US6958388B2 (en) | 2001-04-06 | 2005-10-25 | Maxygen, Aps | Interferon gamma polypeptide variants |
| EP1425304B9 (de) | 2001-07-11 | 2010-09-08 | Maxygen, Inc. | G-csf konjugate |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| US7138134B2 (en) * | 2001-12-18 | 2006-11-21 | Arizona Health Consulting Group, Llc | Preparation and administration of jojoba product for reducing weight, fat and blood lipid levels |
| CA2491178A1 (en) | 2002-07-03 | 2004-01-15 | Maxygen Holdings Ltd. | Full-length interferon gamma polypeptide variants |
| EP1491554A1 (de) * | 2003-06-23 | 2004-12-29 | CONARIS research institute AG | PEGlierte lösliche gp130-Dimeren geignet als Medikament |
| ES2383300T3 (es) * | 2003-11-13 | 2012-06-20 | Hanmi Holdings Co., Ltd | Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación |
| CA2553528C (en) * | 2004-01-21 | 2012-12-04 | Nektar Therapeutics Al, Corporation | Method of preparing propionic acid-terminated polymers |
| BRPI0507169A (pt) | 2004-02-02 | 2007-06-26 | Ambrx Inc | polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos |
| US7632924B2 (en) | 2004-06-18 | 2009-12-15 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
| WO2006091231A2 (en) | 2004-07-21 | 2006-08-31 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| WO2006034373A2 (en) * | 2004-09-17 | 2006-03-30 | Biomarin Pharmaceutical Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| EP1674113A1 (de) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol) |
| CN103520735B (zh) | 2004-12-22 | 2015-11-25 | Ambrx公司 | 包含非天然编码的氨基酸的人生长激素配方 |
| EP1836316A4 (de) | 2004-12-22 | 2009-07-22 | Ambrx Inc | Verfahren zur expression und reinigung von rekombinantem menschlichem wachstumshormon |
| EP1836298B1 (de) | 2004-12-22 | 2012-01-18 | Ambrx, Inc. | Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon |
| BRPI0519430A2 (pt) | 2004-12-22 | 2009-02-10 | Ambrx Inc | hormânio do crescimento humano modificado |
| EP1868652A2 (de) * | 2005-04-05 | 2007-12-26 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Verfahren zur abschirmung von funktionalen stellen oder epitopen auf proteinen |
| DE102005016824A1 (de) | 2005-04-12 | 2006-10-19 | Giesecke & Devrient Gmbh | Vorrichtung und Verfahren zur Prüfung von Wertdokumenten |
| US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| KR20080027291A (ko) | 2005-06-01 | 2008-03-26 | 맥시겐 홀딩스 엘티디 | 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법 |
| AU2006255122B2 (en) | 2005-06-03 | 2010-10-21 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| US7785834B2 (en) * | 2005-11-10 | 2010-08-31 | Ercole Biotech, Inc. | Soluble TNF receptors and their use in treatment of disease |
| WO2007058894A2 (en) * | 2005-11-10 | 2007-05-24 | The University Of North Carolina At Chapel Hill | Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
| DK2339014T3 (en) | 2005-11-16 | 2015-07-20 | Ambrx Inc | Methods and compositions comprising non-natural amino acids |
| US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| US8841255B2 (en) * | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7534595B2 (en) | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| EP2064333B1 (de) | 2006-09-08 | 2014-02-26 | Ambrx, Inc. | Unterdrücker-trna-transkription für wirbeltierzellen |
| CN106008699A (zh) | 2006-09-08 | 2016-10-12 | Ambrx公司 | 经修饰的人类血浆多肽或Fc骨架和其用途 |
| WO2008051383A2 (en) * | 2006-10-19 | 2008-05-02 | Amgen Inc. | Use of alcohol co-solvents to improve pegylation reaction yields |
| US20090264353A1 (en) * | 2007-10-19 | 2009-10-22 | Santaris Pharma A/S | Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease |
| PE20081140A1 (es) * | 2006-10-25 | 2008-09-22 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
| CN107501407B (zh) | 2007-03-30 | 2022-03-18 | Ambrx公司 | 经修饰fgf-21多肽和其用途 |
| US8114630B2 (en) | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| EP2162540A2 (de) | 2007-05-22 | 2010-03-17 | Amgen Inc. | Zusammensetzungen und verfahren zur herstellung biologisch aktiver fusionsproteine |
| US7560263B2 (en) | 2007-08-17 | 2009-07-14 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| MX2010005317A (es) | 2007-11-20 | 2010-06-02 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
| MX344166B (es) | 2008-02-08 | 2016-12-07 | Ambrx Inc | Leptina-polipeptidos modificados y sus usos. |
| CN102131516B (zh) | 2008-06-27 | 2016-03-16 | 杜克大学 | 包含弹性蛋白样肽的治疗剂 |
| CN102159230A (zh) | 2008-07-23 | 2011-08-17 | Ambrx公司 | 经修饰的牛g-csf多肽和其用途 |
| WO2010014225A2 (en) * | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| BR122012024318A2 (pt) | 2008-09-26 | 2019-07-30 | Ambrx, Inc. | Polipeptídeos modificados de eritropoetina animal e seus usos |
| AU2009296267B2 (en) | 2008-09-26 | 2013-10-31 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
| JP2013512674A (ja) * | 2009-12-02 | 2013-04-18 | アクセルロン ファーマ， インコーポレイテッド | Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法 |
| MX349301B (es) | 2009-12-21 | 2017-07-21 | Ambrx Inc | Polipéptidos de somatotropina bovina modificados y sus usos. |
| BR112012015597A2 (pt) | 2009-12-21 | 2017-01-31 | Ambrx Inc | peptídeos de somatotropina suínos modificados e seus usos |
| ES2690542T3 (es) | 2010-02-04 | 2018-11-21 | Biomarin Pharmaceutical Inc. | Método para purificar variantes de fenilalanina amoníaco-liasa procariotas |
| US9782454B2 (en) | 2010-04-22 | 2017-10-10 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
| JP2012034668A (ja) * | 2010-08-12 | 2012-02-23 | Tohoku Univ | ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用 |
| EA030886B1 (ru) | 2010-08-17 | 2018-10-31 | Амбркс, Инк. | Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
| PH12013501865A1 (en) | 2011-03-16 | 2014-01-06 | Amgen Inc | Potent and selective inhibitors of nav1.3 and nav1.7 |
| DK2694095T3 (en) | 2011-04-05 | 2018-05-28 | Longevity Biotech Inc | COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME |
| EP2718328A4 (de) | 2011-06-08 | 2014-12-24 | Acceleron Pharma Inc | Zusammensetzungen und verfahren zur erhöhung der halbwertszeit von serum |
| US20160067347A1 (en) | 2012-12-20 | 2016-03-10 | Amgen Inc. | Apj receptor agonists and uses thereof |
| WO2014165277A2 (en) | 2013-03-12 | 2014-10-09 | Amgen Inc. | POTENT AND SELECTIVE INHIBITORS OF Nav1.7 |
| WO2014145718A2 (en) | 2013-03-15 | 2014-09-18 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
| WO2015191781A2 (en) | 2014-06-10 | 2015-12-17 | Amgen Inc. | Apelin polypeptides |
| CN114805532A (zh) | 2014-10-24 | 2022-07-29 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| MX2018005232A (es) | 2015-11-03 | 2018-08-15 | Ambrx Inc | Anticuerpos anti-cd3 novedosos y sus usos. |
| CN114835793A (zh) * | 2015-11-16 | 2022-08-02 | Ubi蛋白公司 | 用于延长蛋白质半衰期的方法 |
| US20190201491A1 (en) | 2016-08-22 | 2019-07-04 | Elanco Us Inc. | Bovine fibroblast growth factor 21 and ketosis in dairy cattle |
| PE20191716A1 (es) | 2017-02-08 | 2019-12-05 | Bristol Myers Squibb Co | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos |
| SG11202001379WA (en) | 2017-09-08 | 2020-03-30 | Bristol Myers Squibb Co | Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) |
| MX2020010104A (es) | 2018-03-29 | 2020-11-06 | Ambrx Inc | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado. |
| KR20210027426A (ko) | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf21 제제 |
| MX2021002301A (es) | 2018-08-28 | 2021-04-28 | Ambrx Inc | Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos. |
| EP3876996A1 (de) | 2018-11-05 | 2021-09-15 | Bristol-Myers Squibb Company | Verfahren zur aufreinigung von pegyliertem protein |
| WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
| JP7842232B2 (ja) * | 2022-02-18 | 2026-04-07 | 江蘇衆紅生物工程創薬研究院有限公司 | 生物活性分子の活性放出制御及び活性徐放を達成する方法及びその薬物への応用 |
| WO2024077277A1 (en) | 2022-10-07 | 2024-04-11 | Ambrx, Inc. | Drug linkers and antibody conjugates thereof |
| WO2024178310A1 (en) | 2023-02-23 | 2024-08-29 | Ambrx, Inc. | Trop2-directed antibody-drug conjugates and uses thereof |
| AU2024329469A1 (en) | 2023-08-22 | 2026-04-09 | Ambrx, Inc. | Anti-psma adc conjugate compositions and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5235028A (en) | 1990-08-31 | 1993-08-10 | University Of Minnesota | Polyethylene glycol derivatives for solid-phase applications |
| ATE240740T1 (de) * | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| IT1260468B (it) | 1992-01-29 | 1996-04-09 | Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole | |
| GB9225448D0 (en) | 1992-12-04 | 1993-01-27 | Erba Carlo Spa | Improved synthesis of polymer bioactive conjugates |
| CA2139385C (en) * | 1994-02-04 | 2001-12-25 | Gottfried Alber | Products containing g-csf and tnf binding protein |
| WO1996011213A1 (en) | 1994-10-07 | 1996-04-18 | Amgen Boulder Inc. | Dimeric il-4 inhibitors |
| DK0851925T3 (da) | 1995-09-21 | 2005-11-28 | Genentech Inc | Humane Væksthormonvarianter |
| US5882141A (en) | 1996-08-02 | 1999-03-16 | Nibco, Inc. | Low energy precision flooding irrigation apparatus and method |
| JP2001511162A (ja) | 1997-02-06 | 2001-08-07 | ノボ ノルディスク アクティーゼルスカブ | 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体 |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
-
1998
- 1998-06-22 US US09/102,530 patent/US6451986B1/en not_active Expired - Lifetime
-
1999
- 1999-06-18 CA CA002331337A patent/CA2331337C/en not_active Expired - Fee Related
- 1999-06-18 AT AT99930486T patent/ATE360033T1/de active
- 1999-06-18 ES ES99930486T patent/ES2285843T3/es not_active Expired - Lifetime
- 1999-06-18 WO PCT/US1999/013953 patent/WO1999067291A2/en not_active Ceased
- 1999-06-18 EP EP99930486A patent/EP1090036B1/de not_active Expired - Lifetime
- 1999-06-18 AU AU47020/99A patent/AU767630B2/en not_active Ceased
- 1999-06-18 NZ NZ509424A patent/NZ509424A/en unknown
- 1999-06-18 DE DE69935855T patent/DE69935855T2/de not_active Expired - Lifetime
- 1999-06-18 EP EP07003818A patent/EP1829554A3/de not_active Withdrawn
- 1999-06-18 JP JP2000555941A patent/JP3578991B2/ja not_active Expired - Fee Related
-
2000
- 2000-05-26 US US09/580,181 patent/US6441136B1/en not_active Expired - Lifetime
- 2000-05-26 US US09/580,235 patent/US6433158B1/en not_active Expired - Lifetime
-
2002
- 2002-09-12 US US10/243,230 patent/US7129203B2/en not_active Expired - Lifetime
-
2006
- 2006-10-26 US US11/588,655 patent/US20070048837A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6433158B1 (en) | 2002-08-13 |
| WO1999067291A3 (en) | 2000-03-09 |
| US7129203B2 (en) | 2006-10-31 |
| EP1090036A2 (de) | 2001-04-11 |
| ES2285843T3 (es) | 2007-11-16 |
| JP2002518522A (ja) | 2002-06-25 |
| CA2331337C (en) | 2008-07-29 |
| WO1999067291A2 (en) | 1999-12-29 |
| DE69935855D1 (de) | 2007-05-31 |
| AU4702099A (en) | 2000-01-10 |
| JP3578991B2 (ja) | 2004-10-20 |
| AU767630B2 (en) | 2003-11-20 |
| EP1829554A2 (de) | 2007-09-05 |
| CA2331337A1 (en) | 1999-12-29 |
| US6451986B1 (en) | 2002-09-17 |
| US20030023049A1 (en) | 2003-01-30 |
| US20070048837A1 (en) | 2007-03-01 |
| EP1829554A3 (de) | 2007-09-26 |
| US20020081309A1 (en) | 2002-06-27 |
| DE69935855T2 (de) | 2008-01-10 |
| NZ509424A (en) | 2002-05-31 |
| US6441136B1 (en) | 2002-08-27 |
| EP1090036B1 (de) | 2007-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE360033T1 (de) | Ortsspezifische proteinmodifizierung durch mutagenese | |
| AU6542598A (en) | Site protected protein modification | |
| BR9812267B1 (pt) | Hormônio de crescimento recombinante. | |
| IL130403A (en) | Oil bodies and associated proteins as affinity matrices | |
| MY126352A (en) | Modified/chimeric superantigens and their use | |
| DE69942231D1 (de) | Ortspezifische duale pegylation von proteine | |
| MX9709265A (es) | Superantigenos modificados/quimericos y sus usos. | |
| EP2107376A3 (de) | Zusammensetzung zum Testen glykierter Proteine | |
| CA2155185A1 (en) | Totally synthetic affinity reagents | |
| CY1110877T1 (el) | Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση | |
| DK0909312T3 (da) | Fremgangsmåde til fremstilling af polypeptider | |
| DE69132902D1 (de) | Methoden zur identifizierung heterofunktionaler fusionsproteine | |
| EP1273918A3 (de) | Verfahren zur Selektion evoluierter Bindungspartner mit Hilfe eines nativen Epitops | |
| ZA200007776B (en) | Enzyme-protein complex. | |
| ATE513056T1 (de) | Stabilisierte proteine | |
| FI923915A0 (fi) | Foerbaettrade kimera toxiner. | |
| BR9709569A (pt) | Processo para ativação de proteína desnaturada | |
| DE69902796D1 (de) | Verfahren zur reinigung von biomolekül- oder proteinkomplexen | |
| TR199801027T2 (xx) | Epitelyom te�his ve tedavisi i�in y�ntem. | |
| NO20000731L (no) | Neisseria lactoferinbindingsprotein | |
| DK1137442T3 (da) | Biologisk aktive konjugater havende en detekterbar rapportermoietet og fremgangsmåde til identificering af nævnte derivat | |
| DE59310280D1 (de) | Verfahren zur Herstellung von Konjugaten aus einem spezifischen Bindungspartner und einem kohlenhydrathaltigen Protein | |
| ATE405646T1 (de) | Ein verfahren zum auffinden vom prostatakrebs | |
| AU3733199A (en) | Antibodies and utilization thereof | |
| Yanagisawa et al. | The basic study on the binding reaction between bovine serum albumin and methamphetamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1090036 Country of ref document: EP |